How Much Does Rezdiffra (Resmetirom) Cost in Alabama in 2026?

Alabama Retail Pricing for Rezdiffra in 2026

The average cash-pay price for Rezdiffra at Alabama retail pharmacies sits at $3,500 per month, matching the manufacturer list price set by Madrigal Pharmaceuticals. This price applies to the standard once-daily oral tablet regimen. Without insurance or a discount program, patients face an annual cost of approximately $42,000.

Pricing does not vary significantly between major Alabama pharmacy chains. CVS, Walgreens, and independent pharmacies in Birmingham, Huntsville, Montgomery, and Mobile all report cash prices near the $3,500 mark, since Rezdiffra is a single-source branded product with no generic equivalent available. The FDA granted accelerated approval to resmetirom in March 2024 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced hepatic fibrosis (stages F2-F3), making it the first drug approved specifically for this indication. Because patent exclusivity remains intact and no competitor has reached approval, there is no pricing pressure from generics or biosimilars.

For context, the MAESTRO-NASH trial (N=966) demonstrated that resmetirom 100 mg daily achieved MASH resolution without worsening fibrosis in 29.9% of patients at 52 weeks, compared to 9.7% with placebo [1]. That efficacy data supports the clinical rationale behind payer decisions, but it has not yet translated into universal coverage across Alabama's insurance programs.

Alabama Medicaid Does Not Cover Rezdiffra

Alabama Medicaid does not include Rezdiffra on its preferred drug list as of 2026. Patients enrolled in Alabama Medicaid who have been diagnosed with MASH and liver fibrosis cannot obtain Rezdiffra through their Medicaid benefits at this time.

This gap exists partly because Rezdiffra received accelerated (not full) FDA approval. Many state Medicaid programs defer formulary addition until a drug receives traditional approval based on confirmed clinical endpoints. The ongoing MAESTRO-NASH outcomes extension and the confirmatory MAESTRO-NAFLD-1 trial will likely influence that decision. The American Association for the Study of Liver Diseases (AASLD) has acknowledged resmetirom's role in MASH treatment, but Medicaid formulary committees in Alabama have not yet acted on those recommendations.

Patients on Alabama Medicaid do have limited options. They can request a non-formulary exception through their managed care organization. Success rates for these exceptions vary. A hepatologist's letter documenting fibrosis stage, failed lifestyle interventions, and progression risk strengthens the appeal. Patients may also explore the Madrigal patient assistance program, which provides Rezdiffra at no cost to qualifying uninsured or underinsured individuals.

Commercial Insurance Coverage in Alabama

Several commercial insurers operating in Alabama cover Rezdiffra, though nearly all require prior authorization and step therapy documentation. Blue Cross Blue Shield of Alabama, the state's largest commercial insurer, has added Rezdiffra to its specialty pharmacy formulary with tier 4 or tier 5 placement. Patients typically face a specialty copay ranging from $150 to $500 per month before any manufacturer assistance.

Prior authorization criteria across Alabama commercial plans generally require:

• A confirmed diagnosis of MASH (biopsy or validated non-invasive testing)
• Hepatic fibrosis stage F2 or F3 documented by imaging or elastography
• Failure of or contraindication to lifestyle modifications (diet and exercise for at least 6 months)
• Prescribing by or consultation with a hepatologist or gastroenterologist

UnitedHealthcare, Aetna, and Cigna plans sold in Alabama follow similar authorization pathways. Approval timelines range from 5 to 15 business days. Denials can be appealed, and the AASLD practice guidance on MASH pharmacotherapy serves as useful supporting documentation in appeal letters.

Employer-sponsored plans deserve separate attention. Self-funded employer plans, which cover a majority of commercially insured Alabamians, set their own formulary rules. Some have added Rezdiffra proactively; others have not. Patients should check with their plan's pharmacy benefits manager directly rather than assuming coverage based on the insurer's name alone.

The Madrigal Pharmaceuticals Savings Card

Madrigal Pharmaceuticals offers a copay savings card that reduces out-of-pocket costs for commercially insured patients in Alabama. The card covers up to $13,000 per year in copay assistance, which effectively reduces monthly costs to $0 for most patients whose insurance already covers a portion of the drug's price.

Eligibility requirements are straightforward. Patients must have commercial insurance that covers at least part of Rezdiffra's cost. They cannot be enrolled in any federal or state government program, including Medicare Part D, Medicaid, TRICARE, or VA benefits. Alabama residents with qualifying commercial coverage can enroll online or by phone through Madrigal's patient support hub.

The savings card works at the point of sale. Once activated and linked to the patient's pharmacy profile, it automatically applies at the specialty pharmacy counter. There is no separate reimbursement claim to file.

For patients whose commercial plan denies coverage entirely, the copay card will not help (since it supplements insurance, not replaces it). These patients should pursue Madrigal's separate patient assistance program, which provides Rezdiffra free of charge to individuals meeting income and insurance criteria.

Compounded Resmetirom in Alabama

Compounded resmetirom is available through licensed 503A compounding pharmacies in Alabama. State Board of Pharmacy regulations permit 503A pharmacies to compound resmetirom formulations based on a valid patient-specific prescription from a licensed prescriber.

A few critical distinctions apply. Compounded resmetirom is not FDA-approved. It does not undergo the same bioequivalence testing as the branded Rezdiffra tablet. The FDA's guidance on compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding when a prescriber determines it is medically appropriate for an individual patient. Alabama follows federal 503A rules without additional state-level restrictions that would block compounding of resmetirom specifically.

Pricing from 503A compounding pharmacies varies considerably. Some Alabama compounding pharmacies list resmetirom preparations at substantially lower prices than the branded product, though exact figures depend on the pharmacy, dosage form, and supply chain factors. Patients considering this route should verify that their pharmacy holds current Alabama Board of Pharmacy licensure and maintains appropriate quality controls.

Dr. Zobair Younossi, chairman of the Global NASH Council, has stated: "The approval of resmetirom represents a turning point for patients with MASH who previously had no pharmacologic options. Access and affordability will determine how many patients actually benefit from this advance." That access question is particularly relevant in Alabama, where the gap between Medicaid non-coverage and $3,500 monthly pricing creates a real barrier for many patients with progressive liver disease.

Telehealth Prescribing of Rezdiffra in Alabama

Alabama permits telehealth prescribing of Rezdiffra. Patients can receive a resmetirom prescription from a licensed prescriber conducting a telehealth visit, provided the prescriber holds an active Alabama medical license or practices under the state's interstate telehealth compact agreements.

This matters for patients in rural Alabama counties where hepatology and gastroenterology specialists are scarce. The state has only a handful of hepatologists, concentrated in Birmingham, Huntsville, and Mobile. Telehealth access means a patient in rural Tuscaloosa County or the Wiregrass region does not need to drive hours for the initial evaluation and prescription.

Alabama's telehealth regulations, updated during and after the COVID-19 public health emergency, allow the establishment of a prescriber-patient relationship via audio-video telehealth encounter. Audio-only visits may face additional restrictions depending on the insurer. For specialty drugs like Rezdiffra, most insurers require documentation from the telehealth visit that meets the same clinical criteria as an in-person evaluation, including fibrosis staging results, lab work confirming MASH diagnosis, and notation of prior treatment attempts.

The MAESTRO-NASH trial established that resmetirom 80 mg and 100 mg daily doses produced a statistically significant improvement in the fibrosis endpoint. Specifically, 25.9% of patients on the 80 mg dose achieved at least a one-stage improvement in fibrosis without MASH worsening, compared to 14.2% on placebo (P<0.001) [1]. Telehealth prescribers should use this data alongside individual patient liver biopsy or elastography results to determine appropriate dosing. The labeled starting dose depends on body weight: 80 mg daily for patients weighing <100 kg and 100 mg daily for those weighing 100 kg or more, per the FDA-approved prescribing information.

Strategies to Lower Your Rezdiffra Cost in Alabama

Patients and prescribers in Alabama can use several concrete approaches to reduce the financial burden of Rezdiffra therapy.

Apply for the Madrigal copay card first. Commercially insured patients should enroll before filling their first prescription. The $13,000 annual cap covers most commercial copay obligations entirely.

File a thorough prior authorization. Include FibroScan or MRE results documenting fibrosis stage, ALT/AST trends, and a hepatologist's clinical narrative. Reference the MAESTRO-NASH primary endpoint data and the AASLD's position on resmetirom for F2-F3 MASH. A complete submission reduces the likelihood of denial and delay.

Appeal every first denial. According to data from the American Medical Association, prior authorization denials are overturned on appeal in a significant portion of cases when additional clinical documentation is provided. Alabama patients should request a peer-to-peer review between their hepatologist and the insurer's medical director.

Check patient assistance eligibility. Uninsured patients and those on government programs may qualify for Madrigal's free drug program. Income thresholds and documentation requirements apply, but the program can eliminate cost entirely for qualifying individuals.

Ask about 503A compounding. For patients who cannot access branded Rezdiffra through any coverage pathway, a conversation with their prescriber about compounded resmetirom from a licensed Alabama 503A pharmacy may be appropriate. This is a clinical decision that weighs cost savings against the lack of FDA-approved bioequivalence data.

Use a specialty pharmacy with accumulator protector awareness. Some Alabama commercial plans use copay accumulator adjustment programs that prevent manufacturer copay cards from counting toward the patient's deductible or out-of-pocket maximum. Patients should ask their pharmacy benefits manager whether their plan uses an accumulator program, as this affects the real value of the Madrigal savings card over the full plan year.

Clinical Monitoring While on Rezdiffra

Regardless of how a patient in Alabama accesses resmetirom, clinical monitoring requirements remain the same. The FDA label requires thyroid function testing (TSH, free T4) before starting therapy and periodically during treatment, since resmetirom is a thyroid hormone receptor-beta agonist. Liver function tests (ALT, AST, bilirubin) should be checked at baseline and during the first year of therapy [2].

The MAESTRO-NASH safety data showed that serious adverse events occurred at similar rates in the resmetirom and placebo groups. The most common adverse events in the resmetirom arms were diarrhea (27.6% vs. 17.5% placebo) and nausea (22.1% vs. 13.6% placebo) [1]. These were generally mild to moderate and decreased after the first few weeks of therapy.

Alabama prescribers should also monitor lipid panels. Resmetirom produced significant reductions in LDL cholesterol (approximately 14% reduction vs. placebo at 52 weeks), apolipoprotein B, and triglycerides in the MAESTRO-NASH population [1]. This lipid-lowering effect, while beneficial, may warrant statin dose adjustment in patients on concurrent lipid therapy.

The Endocrine Society's clinical guidance on thyroid hormone analogues emphasizes that selective THR-beta agonism, as achieved by resmetirom, minimizes cardiac and bone effects associated with THR-alpha activation. Still, patients with pre-existing atrial fibrillation or uncontrolled thyroid disease were excluded from MAESTRO-NASH and should be prescribed resmetirom only with close specialist oversight.

Patients filling Rezdiffra at an Alabama specialty pharmacy should expect pharmacist outreach calls for adherence monitoring and side effect screening. Most specialty pharmacies conduct these check-ins monthly. This is standard practice for high-cost specialty drugs and helps catch tolerability issues early before they lead to therapy discontinuation.